CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer’s disease

Hu, Yueming, Meuret, Cristiana, Martinez, Ashley, Yassine, Hussein N., Nedelkov, Dobrin·2021·Journal of Lipid Research
DOI 10.1194/jlr.ra120000919PMC PMC7859854
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.ra120000919

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. Bondarenko, 1999, Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein, J. Lipid Res., 40, 543, 10.1016/S0022-2275(20)32459-7 · DOI
  2. Lambeir, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV, Crit. Rev. Clin. Lab. Sci., 40, 209, 10.1080/713609354 · DOI · Paper page
  3. Fojo, 1986, Human preproapolipoprotein C-II. Analysis of major plasma isoforms, J. Biol. Chem., 261, 9591, 10.1016/S0021-9258(18)67554-4 · DOI
  4. Sacks, 2011, Complexities of plasma apolipoprotein C-III metabolism, J. Lipid Res., 52, 1067, 10.1194/jlr.E015701 · DOI
  5. Fuior, 2019, Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond, Int. J. Mol. Sci., 20, 10.3390/ijms20235939 · DOI · Paper page
  6. Koch, 2001, Characterization of four lipoprotein classes in human cerebrospinal fluid, J. Lipid Res., 42, 1143, 10.1016/S0022-2275(20)31605-9 · DOI · Paper page
  7. Lauer, 1988, Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene, J. Biol. Chem., 263, 7277, 10.1016/S0021-9258(18)68638-7 · DOI
  8. Elliott, 2010, Apolipoproteins in the brain: implications for neurological and psychiatric disorders, Clin. Lipidol., 51, 555, 10.2217/clp.10.37 · DOI · Paper page
  9. Roheim, 1979, Apolipoproteins in human cerebrospinal fluid, Proc. Natl. Acad. Sci. U.S.A., 76, 4646, 10.1073/pnas.76.9.4646 · DOI · Paper page
  10. Koch, 2017, Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma, Alzheimers Dement. (Amst), 6, 182, 10.1016/j.dadm.2017.01.007 · DOI · Paper page
  11. Stukas, 2014, Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus, J. Am. Heart Assoc., 3
  12. Zhou, 2019, Apolipoprotein A-I crosses the blood-brain barrier through clathrin-independent and cholesterol-mediated endocytosis, J. Pharmacol. Exp. Ther, 369, 481, 10.1124/jpet.118.254201 · DOI
  13. Scott, 1985, Localization of genes encoding apolipoproteins CI, CII, and E to the p13----cen region of human chromosome 19, Hum. Genet, 71, 144, 10.1007/BF00283370 · DOI
  14. Zhou, 2014, Association between APOC1 polymorphism and Alzheimer's disease: a case-control study and meta-analysis, PLoS One, 9, e87017, 10.1371/journal.pone.0087017 · DOI · Paper page
  15. Dallinga-Thie, 1996, Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III, J. Lipid Res, 37, 136, 10.1016/S0022-2275(20)37642-2 · DOI
  16. Wyler von Ballmoos, 2015, The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis, J. Clin. Lipidol, 9, 498, 10.1016/j.jacl.2015.05.002 · DOI · Paper page
  17. Ramms, 2018, Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism, Curr. Opin. Lipidol, 29, 171, 10.1097/MOL.0000000000000502 · DOI
  18. Taskinen, 2019, Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD, Curr. Atheroscler. Rep, 21, 27, 10.1007/s11883-019-0791-9 · DOI
  19. Olivieri, 2007, ApoE ε2/ε3/ε4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome, Clin. Exp. Med., 7, 164, 10.1007/s10238-007-0142-y · DOI
  20. Trenchevska, 2015, Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms, Methods, 81, 86, 10.1016/j.ymeth.2015.02.020 · DOI · Paper page
  21. Yassine, 2015, The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides, PLoS One, 10, 10.1371/journal.pone.0144138 · DOI
  22. Koska, 2016, Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes, J. Lipid Res, 57, 894, 10.1194/jlr.P064816 · DOI
  23. Mendoza, 2017, Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions, J. Clin. Lipidol, 11, 224, 10.1016/j.jacl.2016.12.009 · DOI
  24. Kegulian, 2019, ApoC-III glycoforms are differentially cleared by hepatic TRL (triglyceride-rich lipoprotein) receptors, Arterioscler. Thromb. Vasc. Biol, 39, 2145, 10.1161/ATVBAHA.119.312723 · DOI
  25. Tudorache, 2017, Apolipoprotein E - a multifunctional protein with implications in various pathologies as a result of its structural features, Comput. Struct. Biotechnol. J, 15, 359, 10.1016/j.csbj.2017.05.003 · DOI · Paper page
  26. Hansen, 2011, The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis, J. Lipids, 2011, 271062
  27. Trenchevska, 2016, Mass spectrometric immunoassays in characterization of clinically significant proteoforms, Proteomes, 4, 10.3390/proteomes4010013 · DOI
  28. Nedelkov, 2017, Mass spectrometric studies of apolipoprotein proteoforms and their Role in lipid metabolism and type 2 diabetes, Proteomes, 5, 10.3390/proteomes5040027 · DOI
  29. Bernstein, 1987, Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain, Int. J. Dev. Neurosci, 5, 237, 10.1016/0736-5748(87)90034-7 · DOI
  30. Busek, 2008, Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors--good or evil?, Front. Biosci, 13, 2319, 10.2741/2846 · DOI
  31. Skinner, 2015, Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1, Diabetes Ther, 6, 395, 10.1007/s13300-015-0123-1 · DOI
  32. Rozek, 1998, Sequence-specific 1H NMR resonance assignments and secondary structure of human apolipoprotein C-I in the presence of sodium dodecyl sulfate, Biochem. Cell Biology, 76, 267, 10.1139/o98-053 · DOI
  33. Rozek, 1999, Conformation of human apolipoprotein C-I in a lipid-mimetic environment determined by CD and NMR spectroscopy, Biochemistry, 38, 14475, 10.1021/bi982966h · DOI
  34. Edelstein, 1983, In vitro conversion of proapoprotein A-I to apoprotein A-I. Partial characterization of an extracellular enzyme activity, J. Biol. Chem, 258, 11430, 10.1016/S0021-9258(17)44242-6 · DOI
  35. Scanu, 1984, Proteolytic events affecting plasma apolipoproteins at the co- and post-translational levels and after maturation, J. Lipid Res, 25, 1593, 10.1016/S0022-2275(20)34437-0 · DOI
  36. Petit-Turcotte, 2001, Apolipoprotein C-I expression in the brain in Alzheimer's disease, Neurobiol. Dis, 8, 953, 10.1006/nbdi.2001.0441 · DOI · Paper page
  37. Abildayeva, 2008, Human apolipoprotein C-I expression in mice impairs learning and memory functions, J. Lipid Res, 49, 856, 10.1194/jlr.M700518-JLR200 · DOI · Paper page
  38. Balazs, 2004, Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model, J. Neurochem, 89, 939, 10.1111/j.1471-4159.2004.02373.x · DOI
  39. Wilson, 2007, A structural core within apolipoprotein C-II amyloid fibrils identified using hydrogen exchange and proteolysis, J. Mol. Biol, 366, 1639, 10.1016/j.jmb.2006.12.040 · DOI
  40. Safi, 2001, A proteolytic method for distinguishing between lipid-free and lipid-bound apolipoprotein A-I, J. Lipid Res., 42, 864, 10.1016/S0022-2275(20)31649-7 · DOI
  41. Dal Magro, 2019, The extent of human apolipoprotein A-I lipidation strongly affects the β-amyloid efflux across the blood-brain barrier in vitro, Front. Neurosci., 13, 10.3389/fnins.2019.00419 · DOI
  42. Guyton, 1998, Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid, J. Neurochem, 70, 1235, 10.1046/j.1471-4159.1998.70031235.x · DOI · Paper page
  43. Holzer, 2016, Refined purification strategy for reliable proteomic profiling of HDL2/3: Impact on proteomic complexity, Sci. Rep, 6, 38533, 10.1038/srep38533 · DOI
  44. Marmillot, 1999, Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver esterified cholesterol to the liver, Metabolism, 48, 1184, 10.1016/S0026-0495(99)90136-1 · DOI
  45. Kawasaki, 2009, Sialic acid moiety of apolipoprotein E and its impact on the formation of lipoprotein particles in human cerebrospinal fluid, Clin. Chim. Acta, 402, 61, 10.1016/j.cca.2008.12.018 · DOI
  46. Agnani, 1991, Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells, Arterioscler. Thromb, 11, 1021, 10.1161/01.ATV.11.4.1021 · DOI
  47. Kowal, 1990, Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein, J. Biol. Chem, 265, 10771, 10.1016/S0021-9258(18)87014-4 · DOI · Paper page
  48. Gordts, 2018, The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis, Matrix Biol, 71-72, 262, 10.1016/j.matbio.2018.05.010 · DOI
  49. Meaney, 2001, Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study, J. Lipid Res, 42, 70, 10.1016/S0022-2275(20)32337-3 · DOI
  50. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  51. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A, 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  52. Farrer, 1997, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA, 278, 1349, 10.1001/jama.1997.03550160069041 · DOI · Paper page
  53. Poduslo, 1998, The apolipoprotein CI A allele as a risk factor for Alzheimer's disease, Neurochem. Res, 23, 361, 10.1023/A:1022409617539 · DOI
  54. Ki, 2002, Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer's disease, Neurosci. Lett, 319, 75, 10.1016/S0304-3940(01)02559-9 · DOI · Paper page
  55. Cudaback, 2012, Apolipoprotein C-I is an APOE genotype-dependent suppressor of glial activation, J. Neuroinflammation, 9, 192, 10.1186/1742-2094-9-192 · DOI · Paper page
  56. Skjot-Arkil, 2010, Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers, Assay Drug Dev. Technol, 8, 542, 10.1089/adt.2009.0258 · DOI
  57. Dafnis, 2010, An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42, J. Neurochem., 115, 873, 10.1111/j.1471-4159.2010.06756.x · DOI · Paper page
  58. Burtenshaw, 2019, Reactive oxygen species (ROS), intimal Thickening, and Subclinical Atherosclerotic Disease, Front. Cardiovasc. Med, 6, 10.3389/fcvm.2019.00089 · DOI
  59. Rohn, 2013, Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease, Int. J. Mol. Sci., 14, 14908, 10.3390/ijms140714908 · DOI
  60. Medeiros, 2004, Fibrillar amyloid protein present in atheroma activates CD36 signal transduction, J. Biol. Chem, 279, 10643, 10.1074/jbc.M311735200 · DOI
  61. Brecht, 2004, Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice, J. Neurosci., 24, 2527, 10.1523/JNEUROSCI.4315-03.2004 · DOI · Paper page
  62. Huang, 2001, Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons, Proc. Natl. Acad. Sci. U.S.A., 98, 8838, 10.1073/pnas.151254698 · DOI · Paper page
  63. O'Brien, 1998, Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins, Circulation, 98, 519, 10.1161/01.CIR.98.6.519 · DOI
  64. Namba, 1991, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, Brain Res, 541, 163, 10.1016/0006-8993(91)91092-F · DOI · Paper page
  65. Wisniewski, 1997, Biology of A beta amyloid in Alzheimer's disease, Neurobiol. Dis, 4, 313, 10.1006/nbdi.1997.0147 · DOI · Paper page
  66. Olivieri, 2007, ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome, Clin. Exp. Med, 7, 164, 10.1007/s10238-007-0142-y · DOI
  67. Mann, 1997, Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor, J. Biol. Chem, 272, 31348, 10.1074/jbc.272.50.31348 · DOI
  68. Shih, 2014, Apolipoprotein C-III is an amyloid-Œ≤-binding protein and an early marker for Alzheimer's disease, J. Alzheimers Dis, 41, 855, 10.3233/JAD-140111 · DOI
  69. Yang, 1999, Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner, Neuroscience, 90, 1217, 10.1016/S0306-4522(98)00561-2 · DOI · Paper page
  70. Li, 2001, Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates, J. Biol. Chem, 276, 18000, 10.1074/jbc.M101589200 · DOI · Paper page
  71. Fu, 2016, Apolipoprotein E lipoprotein particles inhibit amyloid-beta uptake through cell surface heparan sulphate proteoglycan, Mol. Neurodegener, 11, 37, 10.1186/s13024-016-0099-y · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Hu, Y., Meuret, C., Martinez, A., Yassine, H. N., & Nedelkov, D.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2021
Volume
62
Pages
100014
ISSN
0022-2275
DOI
10.1194/jlr.ra120000919
PMC
PMC7859854
Cited by
18
References
7
Language
en
Licence
Funders
  • National Institutes of Health (R01AG054434, R01AG055770, R01AG067063, R21AG056518)
  • National Institute on Aging (P50AG05142)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review